Post-Treatment Platelet Reactivity Predicts Long-Term Adverse Events Better Than the Response to Clopidogrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome;La reactividad plaquetaria post-tratamiento predice los eventos adversos a largo plazo mejor que la respuesta al clopidogrel en pacientes con síndrome coronario agudo sin elevación del ST

Revista Espanola de Cardiologia

Volumn 62, Issue 2, 2009, Pages 126-135

  de Miguel Castro, Antonio ^a   Cuellas Ramón, Carlos ^a   Diego Nieto, Alejandro ^a   Samaniego Lampón, Beatriz ^a   Alonso Rodríguez, David ^a   Fernández Vázquez, Felipe ^a   Alonso Orcajo, Norberto ^a   Carbonell de Blas, Raúl ^a   Pascual Vicente, Cristina ^a   Pérez de Prado, Armando ^a  

^a HOSPITAL DE LEÓN   (Spain)

Author keywords

Acute coronary syndrome; Major adverse cardiovascular events; Platelet aggregation inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY BYPASS GRAFT; DEATH; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; STROKE; THROMBOCYTE; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD PLATELETS; CORONARY ARTERY BYPASS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 60449116448     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(09)70154-X     Document Type: Article

References (35)

1. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
2. Steinhubl S.R., Berger P.B., Mann III J.T., Fry E.T., DeLago A., Wilmer C., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
3. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCICURE study. Lancet 358 (2001) 527-533
4. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
5. Gurbel P.A., and Tantry U.S. Aspirin and clopidogrel resistance: Consideration and management. J Interv Cardiol 19 (2006) 439-448
6. Jaremo P., Lindahl T.L., Fransson S.G., and Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 252 (2002) 233-238
7. O'Donoghue M., and Wiviott S.D. Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?. Circulation 114 (2006) e600-e606
8. Lev E.I., Patel R.T., Maresh K.J., Guthikonda S., Granada J., DeLao T., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
9. Wang T.H., Bhatt D.L., and Topol E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27 (2006) 647-654
10. Hochholzer W., Trenk D., Bestehorn H.P., Fischer B., Valina C.M., Ferenc M., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006) 1742-1750
11. Geisler T., Langer H., Wydymus M., Gohring K., Zurn C., Bigalke B., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27 (2006) 2420-2425
12. Cuisset T., Frere C., Quilici J., Morange P.E., Nait-Saidi L., Carvajal J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48 (2006) 1339-1345
13. Campo G., Valgimigli M., Gemmati D., Percoco G., Tognazzo S., Cicchitelli G., et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol 48 (2006) 2178-2185
14. Gurbel P.A., Bliden K.P., Guyer K., Cho P.W., Zaman K.A., Kreutz R.P., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 46 (2005) 1820-1826
15. Samara W.M., Bliden K.P., Tantry U.S., and Gurbel P.A. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 115 (2005) 89-94
16. Bliden K.P., DiChiara J., Tantry U.S., Bassi A.K., Chaganti S.K., and Gurbel P.A. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol 49 (2007) 657-666
17. Angiolillo D.J., Bernardo E., Sabate M., Jimenez-Quevedo P., Costa M.A., Palazuelos J., et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50 (2007) 1541-1547
18. Price M.J., Endemann S., Gollapudi R.R., Valencia R., Stinis C.T., Levisay J.P., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 (2008) 992-1000
19. Quinn M.J., Murphy R.T., Dooley M., Foley J.B., and Fitzgerald D.J. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion. J Pharmacol Exp Ther 297 (2001) 496-500
20. Van Werkum J.W., Van der Stelt C.A., Seesing T.H., Hackeng C.M., and ten Berg J.M. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 4 (2006) 2516-2518
21. Von Beckerath N., Pogatsa-Murray G., Wieczorek A., Sibbing D., Schomig A., and Kastrati A. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 95 (2006) 910-911
22. Wheeler G.L., Braden G.A., Steinhubl S.R., Kereiakes D.J., Kottke-Marchant K., Michelson A.D., et al. The Ultegra rapid platelet function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J 143 (2002) 602-611
23. Steinhubl S.R., Talley J.D., Braden G.A., Tcheng J.E., Casterella P.J., Moliterno D.J., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103 (2001) 2572-2578
24. Chesebro J.H., Knatterud G., Roberts R., Borer J., Cohen L.S., Dalen J., et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76 (1987) 142-154
25. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
26. Geisler T., Kapp M., Gohring-Frischholz K., Daub K., Dosch C., Bigalke B., et al. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 94 (2008) 743-747
27. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
28. Montalescot G., Sideris G., Meuleman C., Bal-dit-Sollier C., Lellouche N., Steg P.G., et al. A randomized comparison of high clopidogrel loading doses in patients with non-STsegment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 48 (2006) 931-938
29. Von Beckerath N., Taubert D., Pogatsa-Murray G., Schomig E., Kastrati A., and Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112 (2005) 2946-2950
30. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., and Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111 (2005) 2099-2106
31. ACC/AHA/SCAI Practice Guidelines, February 21, 2006. Circulation. 2006;113:e166-286.
32. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115 (2007) 708-716
33. Kastrati A., Von Beckerath N., Joost A., Pogatsa-Murray G., Gorchakova O., and Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 110 (2004) 1916-1919
34. Moliterno D.J., and Steinhubl S.R. Clopidogrel for percutaneous coronary revascularization: time for more pretreatment, retreatment, or both?. JAMA 294 (2005) 1271-1273
35. Bonello L., Camoin-Jau L., Arques S., Boyer C., Panagides D., Wittenberg O., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51 (2008) 1404-1411